Investors aiming for above-average returns often turn to the practice of stock picking. Skillful choices in individual stocks can be a catalyst for substantial wealth growth.
In the latest session, Vincerx Pharma Inc (NASDAQ: VINC) closed at $0.84 up 15.08% from its previous closing price of $0.73. In other words, the price has increased by $15.08 from its previous closing price. On the day, 0.72 million shares were traded. VINC stock price reached its highest trading level at $0.88 during the session, while it also had its lowest trading level at $0.737.
Ratios:
For a deeper understanding of Vincerx Pharma Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 2.63 and its Current Ratio is at 2.63. In the meantime, Its Debt-to-Equity ratio is 0.22 whereas as Long-Term Debt/Eq ratio is at 0.12.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, H.C. Wainwright on January 14, 2022, initiated with a Buy rating and assigned the stock a target price of $25.
On December 23, 2021, Cantor Fitzgerald started tracking the stock assigning a Overweight rating and target price of $25.
On November 01, 2021, SVB Leerink started tracking the stock assigning a Outperform rating and target price of $24.SVB Leerink initiated its Outperform rating on November 01, 2021, with a $24 target price.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Aug 11 ’23 when Seelenberger Alexander A. bought 10,500 shares for $0.95 per share. The transaction valued at 9,968 led to the insider holds 30,280 shares of the business.
Hamdy Ahmed MD bought 5,400 shares of VINC for $5,167 on Aug 10 ’23. The insider now owns 96,060 shares after completing the transaction at $0.96 per share. On Aug 10 ’23, another insider, THOMAS TOM C, who serves as the insider of the company, bought 5,000 shares for $0.95 each. As a result, the insider paid 4,750 and bolstered with 219,935 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, VINC now has a Market Capitalization of 17989398 and an Enterprise Value of 7709388.
Stock Price History:
The Beta on a monthly basis for VINC is 1.12, which has changed by -0.4580645 over the last 52 weeks, in comparison to a change of 0.24191546 over the same period for the S&P500. Over the past 52 weeks, VINC has reached a high of $9.37, while it has fallen to a 52-week low of $0.61. The 50-Day Moving Average of the stock is -79.02%, while the 200-Day Moving Average is calculated to be -51.36%.
Shares Statistics:
For the past three months, VINC has traded an average of 1.18M shares per day and 641190 over the past ten days. A total of 21.41M shares are outstanding, with a floating share count of 13.47M. Insiders hold about 37.11% of the company’s shares, while institutions hold 40.80% stake in the company. Shares short for VINC as of 1713139200 were 1196271 with a Short Ratio of 1.02, compared to 1710460800 on 863696. Therefore, it implies a Short% of Shares Outstanding of 1196271 and a Short% of Float of 7.93.
Earnings Estimates
Investors are eagerly awaiting the insights provided by 2.0 analysts currently analyzing and rating the stock of Vincerx Pharma Inc (VINC).On average, analysts expect EPS of -$0.23 for the current quarter, with a high estimate of -$0.21 and a low estimate of -$0.26, while EPS last year was -$0.68. The consensus estimate for the next quarter is -$0.22, with high estimates of -$0.18 and low estimates of -$0.27.
Analysts are recommending an EPS of between -$0.74 and -$1.31 for the fiscal current year, implying an average EPS of -$1.02. EPS for the following year is -$0.94, with 2.0 analysts recommending between -$0.77 and -$1.11.
